AG
AMBI

Artal Group’s Ambit Biosciences Corp AMBI Stock Holding History

Artal Group’s Portfolio AMBI Stock Details AMBI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-250,000
Closed -$1.73M – 101
2014
Q2 		$1.73M Hold
250,000
– – 0.07% 80
2014
Q1 		$2.28M Hold
250,000
– – 0.08% 87
2013
Q4 		$2.41M Buy
+250,000
New +$3.34M 0.09% 78

Other funds holding AMBI

FCMI
Foresite Capital Management I Larkspur, California $21.4M AUM 80.48% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
GCM
Gruss Capital Management New York $715M AUM 9.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
U
UBS Zurich, Switzerland $136B AUM 16.36% 1-Year Est. Return
GP
GLG Partners London, United Kingdom $2.14B AUM 21.14% 1-Year Est. Return
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return

Artal Group's AMBI Position: Q3 2014 in Review

Artal Group sold out of Ambit Biosciences Corp (AMBI) in Q3 2014, closing a stake of 250,000 shares — an estimated $1.73M sold.

Artal Group first reported a position in AMBI in Q4 2013 and held it in 3 quarters. The position peaked at $2.41M in Q4 2013. 49 funds tracked by Wall St. Rank hold AMBI as of Q3 2014.

  • Artal Group reported no remaining Ambit Biosciences Corp position as of Q3 2014 after selling out during the quarter.
  • Artal Group sold 250,000 Ambit Biosciences Corp shares in Q3 2014, an estimated $1.73M.
  • Artal Group first reported a position in Ambit Biosciences Corp in Q4 2013 and held it in 3 quarters.
  • Artal Group's Ambit Biosciences Corp position peaked at $2.41M in Q4 2013.
  • 49 funds tracked by Wall St. Rank held Ambit Biosciences Corp as of Q3 2014.

Based on Artal Group's 13F filing for Q3 2014, filed 13 Nov 2014.